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relative risk reduction that we found was similar to those
published on the basis of results from RCTs.
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OBJECTIVES: Dissemination of medical knowledge and
implementation of knowledge needs to be better under-
stood. Academic detailing can effectively change prescrib-
ing, but it is very resource demanding. This research com-
pares the effect of an educational intervention through
individual outreach visits and through a group approach,
using academic detailing.
METHODS: We conducted a randomized controlled trial
to measure the effect of two educational programs on pre-
scribing (individual intervention arm and group interven-
tion arm versus control arm) to reduce anticholinergic anti-
depressant (AAD) prescribing for the elderly. We included
all General Practitioners (GPs) and pharmacists (approx.
230) in the southwest Netherlands health district and used a
database covering all prescriptions to persons insured by the
national health insurance system in this area (approx.
240,000).
RESULTS: In the individual arm 43 of 70 GPs were visited;
in the group arm 5 of 7 groups (41 of 52 GPs) agreed to join
the program. Using an intention to treat analyses there was
a reduction in the incidence of AAD in elderly of 26% (95%
confidence interval 4%–48%) in the individual arm and
of 45% (8%–67%) in the group arm. The use of non-AAD
in the elderly increased by 40% (6%–83%) in the individual
arm and by 29% (7%–79%) in the group arm.
CONCLUSIONS: Both the individual and the group ap-
proach significantly decreased the incidence of AAD and in-
creased the incidence of non-AAD use in the elderly. These
approaches are practical means of improving the clinical ap-
propriateness of medication use on a large scale among pri-
mary care physicians.
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Dissention exists among health economists regarding the
measurement and inclusion of productivity costs in a cost-
utility analysis. Some health economists believe that produc-
tivity costs are captured by quality-adjusted life years
(QALYs) in the denominator of the cost-utility ratio. Others
argue that productivity costs should be measured mone-
tarily via the friction cost method or the human capital
method, and included in the numerator of the ratio.
OBJECTIVES: (1) To investigate the extent to which
changes in productivity costs are explained by changes in
QALYs. (2) To examine the difference between the hu-
man capital method and the friction cost method.
METHODS: An observational panel study with two sur-
vey waves was used to collect data. Surveys were admin-
istered through face-to-face interviews to a convenience
sample of 102 informal caregivers of the elderly.
RESULTS: Changes in QALYs did not explain absence
from paid labor, reduced productivity during paid labor,
and lost leisure productivity costs. However, changes in
QALYs did account for ten percent of the variance in
changes in lost unpaid labor (F  8.67, P  0.01). Fric-
tion cost estimates were significantly less than human
capital estimates in both the first and second waves of the
study (t  6.96, P  0.01, t  6.47, P  0.01).
CONCLUSIONS: Most productivity cost components
should be valued monetarily, and included in the numer-
ator of a cost-utility ratio. If the friction cost method is
used, rather than the human capital method, smaller esti-
mates of productivity costs will be obtained.
ECONOMIC & OUTCOMES STUDY RESULTS OF 
INFECTIOUS AND RESPIRATORY DISEASES
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OBJECTIVES: To examine the likely cost savings to the
NHS of reclassification of a medicine from prescription
only medicine (POM) to pharmacy (P) status.
METHODS: We used the General Practice Research Data-
base to look at changes in GP prescriptions for acyclovir
cream 5% before and after reclassification. To control for
the effects of prescription charges we categorized the data
into three patient age groups: 0–19, 20–59 and 60.
RESULTS: There was a 49% reduction in prescribing
rate in the 20–59 age group which has no prescription
charge exemptions on age grounds. For an average sized
general practice about 65 consultations would be saved
annually. Annual savings to the National Health Service
due to reclassification of one product are calculated to be
more than £5 million.
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CONCLUSIONS: As well as resulting in cost savings, re-
classification will tend to improve equity of access to the
medicine. Given the potential for large cost savings to the
NHS and society we recommend that the status of POMs
be reviewed on a more frequent basis than the current in-
terval of five years.
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OBJECTIVES: To assess the degree of inadequacy of anti-
biotic utilisation and its associated costs in PHC centers in
Catalonia.
METHOD: We used an observational design. The uni-
verse of the study was all the visits due to infectious dis-
eases to PHC doctors of the 40 basic health care areas of
the Region “Costa de Ponent”. 2.500 visits were included
in the sample, corresponding to 29 centers and 251 pre-
scribers. The source of information was the clinical
records. The adequacy of the treatment prescribed was as-
sessed with reference to the recommendations of the Cata-
lan Society of Family Medicine, adjusted to the pattern of
antimicrobial resistance in the area. The efficiency of the
prescription was assessed taking as a reference the mini-
mum cost required by an adequate treatment that could be
achieved by using the cheapest alternatives.
RESULTS: The number of valid observations (visits due to
infectious diseases) was 2,470. In 1,349 cases (54.6%) an
antibiotic was prescribed. The treatment prescribed was ad-
equate in 56.3% of the cases. The treatment was assessed as
inadequate in 43.7% of the cases. In 92 cases an antibiotic
was required and not prescribed and in 680 cases an antibi-
otic was not required but prescribed and in the remaining
294 cases an antibiotic was required, but the antibiotic pre-
scribed was not the recommended one. The total cost of the
antibiotics prescribed was 3.5 million PTA. of which 2.4
million (68.7%) could apparently have been avoided. 1.9
million corresponded to clinically inadequate prescriptions
and the remaining 0.5 corresponded to clinically adequate
prescriptions that used brands of higher price than the low-
est priced alternatives available on the market.
CONCLUSIONS: Inadequate use of antibiotic causes un-
necessary costs to the health system and increases antibi-
otic resistance. Action should be taken to improve the ade-
quacy and efficiency of prescribing habits.
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OBJECTIVE: To investigate the incremental cost of
nosocomial pneumonia (NP) from the perspective of a
1,800 bed University hospital and health insurance funds
by means of matched pair analysis of patients with and
without NP (CDC criteria).
METHODS: Analyses were based on patient data gath-
ered between 2/97 and 3/99, a) prospectively in 5 ICUs
and b) retrospectively in 2 ICUs and the general wards to
which patients were transferred.
RESULTS: Prospectively, out of 114 patients, 29 pairs
could be matched. The incremental length of stay (LOS)
per NP-patient was 6.6 days (45%; 95% CI: 2.75–
10.43) resulting in total incremental cost of DM 14,606
per patient (95% CI: 5,285–23,927). Antibiotic cost was
DM500 higher (150%, 95% CI: 105–896), and cost
for microbiology DM486 higher (80%) for NP-patients
than for controls. From the health insurance fund per-
spective cost was DM7,988 (30%; 95% CI: 5,281–
10,694) higher. Retrospectively, out of 89 patients 37
pairs could be matched. LOS in ICU was 14 days longer
for NP-patients (80%; 95% CI: 11.2–16.9), the entire
LOS 10.1 days (190%; 95% CI: 6.6–13.7) respectively
which resulted in incremental cost of DM29,610 per pa-
tient from the hospital’s perspective (270%; 95% CI:
23,054–36,174) and DM18,000 (245%; 95% CI:
14,885–21,020) from health insurance fund perspective.
Incremental cost for antibiotics amounted to DM1,042
(870%; 95% CI: 718–1,367), cost for microbiology to
DM825 (384%).
CONCLUSION: The study not only gives insight into the
structure of incremental cost caused by NP but also
shows that based on a conservative cost calculation the
incremental cost per NP-patient is higher for the hospital
than for health insurance funds which indicates a signifi-
cant financial deficit for the hospital. Antibiotics and mi-
crobiology together only contribute 6.8% to incremental
cost. Therefore in a cost saving initiative their close rela-
tionship to LOS must be considered.
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OBJECTIVES: To measure cost-effectiveness of the two
most commonly used inhaled corticosteroids in asthma: Pul-
